Eleison Pharmaceuticals is a clinical stage, specialty pharmaceutical company that focuses on developing drug candidates for orphan oncology indications, addressing areas of high unmet medical need in cancer treatment. With a strategy of acquiring late-stage compounds, Eleison aims to pursue a lower cost and accelerated development pathway for its products. Leveraging its industry experience, oncology therapeutics knowledge, and development expertise, Eleison identifies, develops, and commercializes product candidates that have strong market potential and fulfill unmet medical needs in cancer treatment.

The company's pharmaceutical business and drug development leadership team provide a significant competitive advantage in designing highly efficient clinical programs. Eleison also maximizes market exclusivity through its substantial intellectual property and orphan drug designations. The company's regulatory strategy prioritizes the fastest pathway to approval with the highest probability of success.

Eleison intends to collaborate closely with the FDA throughout development and take advantage of the services and assistance offered by the FDA's Office of Orphan Products Development and small business program. While their drug programs are currently in development and not approved for marketing, Eleison will evaluate the economics of marketing their own products versus licensing and third-party arrangements for marketing and distribution in the United States. In other markets, they seek marketing and distribution partners and cost-sharing arrangements